In This Issue

Pharmacogenomics J 6: 153; doi:10.1038/sj.tpj.6500399

Abstract | Full Text | PDF

Pharmacogenomics and regulatory decision making: an international perspective

D L Mendrick, C Brazell, E A Mansfield, R Pietrusko, I Barilero, J Hackett, S Stürzebecher and D Jacobson-Kram

Pharmacogenomics J 6: 154-157; advance online publication, January 17, 2006; doi:10.1038/sj.tpj.6500364

Abstract | Full Text | PDF

Pharmacovigilance in a genomic era

P Farahani and M Levine

Pharmacogenomics J 6: 158-161; advance online publication, January 17, 2006; doi:10.1038/sj.tpj.6500370

Abstract | Full Text | PDF

Pharmacogenetics and pharmacogenomics: origin, status, and the hope for personalized medicine

W Kalow

Pharmacogenomics J 6: 162-165; advance online publication, January 17, 2006; doi:10.1038/sj.tpj.6500361

Abstract | Full Text | PDF

Use of genomic signatures in therapeutics development in oncology and other diseases

R Simon and S-J Wang

Pharmacogenomics J 6: 166-173; advance online publication, January 17, 2006; doi:10.1038/sj.tpj.6500349

Abstract | Full Text | PDF

Influence of phenotype and pharmacokinetics on -blocker drug target pharmacogenetics

A L Beitelshees, I Zineh, H N Yarandi, D F Pauly and J A Johnson

Pharmacogenomics J 6: 174-178; advance online publication, January 10, 2006; doi:10.1038/sj.tpj.6500354

Abstract | Full Text | PDF

Linkage disequilibrium and association with methamphetamine dependence/psychosis of -opioid receptor gene polymorphisms

S Ide, H Kobayashi, H Ujike, N Ozaki, Y Sekine, T Inada, M Harano, T Komiyama, M Yamada, M Iyo, N Iwata, K Tanaka, H Shen, K Iwahashi, M Itokawa, M Minami, M Satoh, K Ikeda and I Sora

Pharmacogenomics J 6: 179-188; advance online publication, January 10, 2006; doi:10.1038/sj.tpj.6500355

Abstract | Full Text | PDF

Estrogen-metabolizing gene polymorphisms in the assessment of female hormone-dependent cancer risk

O N Mikhailova, L F Gulyaeva, A V Prudnikov, A V Gerasimov and S E Krasilnikov

Pharmacogenomics J 6: 189-193; advance online publication, January 10, 2006; doi:10.1038/sj.tpj.6500365

Abstract | Full Text | PDF

Interaction between variation in the D2 dopamine receptor (DRD2) and the neuronal calcium sensor-1 (FREQ) genes in predicting response to nicotine replacement therapy for tobacco dependence

J P Dahl, C Jepson, R Levenson, E P Wileyto, F Patterson, W H Berrettini and C Lerman

Pharmacogenomics J 6: 194-199; advance online publication, January 10, 2006; doi:10.1038/sj.tpj.6500358

Abstract | Full Text | PDF

Relevance of frequent -opioid receptor polymorphisms for opioid activity in healthy volunteers

J Lötsch and G Geisslinger

Pharmacogenomics J 6: 200-210; advance online publication, January 17, 2006; doi:10.1038/sj.tpj.6500362

Abstract | Full Text | PDF

The role of Gilbert's syndrome and frequent NAT2 slow acetylation polymorphisms in the pharmacokinetics of retigabine

R Hermann, J Borlak, U Munzel, G Niebch, U Fuhr, J Maus and K Erb

Pharmacogenomics J 6: 211-219; advance online publication, January 10, 2006; doi:10.1038/sj.tpj.6500359

Abstract | Full Text | PDF